

# **48-hour Review of Travel Restrictions**

### **Purpose**

To provide health advice on continued requirements for travel restrictions. This is the
seventh such review and is current at 1400 on 18 February 2020.

### Key messages

- The Ministry recommends that the current travel restrictions remain in place due to:
  - o no evidence of a sustained decrease in the number of confirmed cases and deaths
  - no softening of risk assessment levels or lifting of travel restrictions in other countries.

#### **Further information**

- On 18 February it is recommended that current travel restrictions remain in place due to:
  - the continuing rising number of cases in mainland China. (24 hour increase of 2,048 confirmed cases),
  - the increasing number of deaths in mainland China. (24 hour increase of 106 deaths)
  - o a number of cases in Australia and the wider Western Pacific Region suggesting risk in the Pacific region remains high.
- Our case definition is broad and adopts a cautious, pre-emptive approach due to the severity of the illness.
- There have been no confirmed cases in New Zealand. Since becoming a notifiable disease on 31 January 2020
- The international picture has not significantly shifted from when the travel restrictions
  were announced. The risk remains high and there is no evidence of a sustained
  decrease in the number of reported cases in mainland China and internationally; and
  there is no suggestion that the overall risk profile is reducing.



Our assessment against the high-level review criteria is:

## Factors for consideration for border measures review

#	High-level considerations	Factors for consideration  NB: these factors have not been weighted or prioritised	Indicate if there has been a change in this factor since the last assessment	Overall comment
		Appropriate guidance documents and management processes available for the health system	There is guidance available on the Ministry of Health website for the health sector and the general public. Regular border advisories are being issued and protocols for the management of the first case in New Zealand have been developed.	The overall status of readiness of New Zealand's health system to respond is good considering the planning readiness. There are response plans in place from the DHBs to the Ministry.  The CMO has engaged widely with clinical colleagues in the sector to
1	Readiness of New Zealand's health system to respond	Scenario planning for potential impact on New Zealand's health system	No, there has been no change.	identify issues.
	to cases and/or outbreak	Current response aims (e.g. stage of NZIPAP)	No Indicative health sector alert code has been issued.	s 9(2)(g)(i)
		Acceptability and feasibility of current measures for key stakeholders	There has been increased concern regarding international students and whether an exemption should be considered.	
		Workforce sustainability of current and/or proposed measures	There have been isolated instances of workforce issues regarding self-isolation.	



			MANATÜ HAUORA	
	Evolving	Epidemiology in China and worldwide e.g. containment or sustained transmission  Risk to NZ from geographical areas of sustained	Sustained transmission is ongoing in mainland China. In other areas, there is more limited transmission. The number of new cases, deaths and recoveries continue to increase. There have now been three deaths outside of China, one each in the Philippines, France and Japan  Risk to New Zealand remains high	The epidemiology of the outbreak has remained constant since the last review. There has been a steady increase in the number of deaths, but the number of laboratory confirmed cases has started to slow down while the number of recovered cases has increased.  China has now ceased routine testing of milder cases and is applying a presumptive clinical diagnosis
2	epidemiology of the outbreak	transmission e.g. New Zealand's immediate neighbours and/or areas of high travel volume	despite introduction and implementation of border	The rapid spread of cases on the cruise
			measures	ship in Japan is of concern as a significant proportion who tested
		Risk assessment update	The risk of importation and transmission remains unchanged for New Zealand.	positive had no symptoms.
		Relevant modelling data	Discussions about support from New Zealand academic institutions are underway with support from Australian modelling experts	
	Emerging evidence	Basic reproduction number (RO)*	Early studies indicate a reproduction number of 2.2 (increased from 1.4)	As more case data is released from mainland China, more accurate assessments on the transmissibility will
3	about transmissibility	Infectiousness	Virus is spread through contact with respiratory droplets in the air and on inanimate objects (surfaces)	be made.



		Incubation period	WHO estimates incubation period of 1 – 12.5 days, median estimate of 5 – 6 days	
4	Emerging evidence about severity of illness	Case fatality risk  Severe disease risk or hospitalisation rate	The fatality rate has remained ~3 percent and the majority are contained within the Hubei province.  There isn't enough data about the number of severe cases apart from the situation in mainland China which has remained steady at ~14 percent.	The emerging evidence about the severity of the illness has remained constant since the first case details were released from mainland China. There isn't sufficient severe case data available for the global situation because the numbers are small in comparison to the numbers in mainland China.
5	WHO advice	Travel restrictions advice  Other advice	WHO still advises travel restrictions are not appropriate.  The overall advice and risk assessment from WHO has remained static since the last review.	WHO advice has remained the same.
6	Public health measures in other countries	Disease control measures in other countries/territories  Exit screening measures at source countries/territories  Measures to prevent or delay virus entering Pacific Island countries/territories	The disease control measures have remained the same.  The measures have remained the same.  The measures have remained the same.	There have been no noteworthy changes in the public health measures in other countries.
7	Other	Effectiveness of current measures	The effectiveness of current measures has stayed the same as	



			there are still no confirmed cases in NZ.	The current measures have been effective in the current phase of the NZIPAP.
		Feasibility of implementing other control measures	More stringent border control and public health measures can be considered if needed.	
		Cost-benefit assessment	No change in the cost-benefit assessment.	

<sup>\*</sup> The R0 is the average number of other people that one infected person will infect, in a completely non-immune population

- This advice has been reviewed by the Ministry's and Prime Minister's Chief Science Advisors, Dr Ian Town and Professor Juliet Gerrard.